SUNNYVALE, Calif., Nov. 29, 2017 /PRNewswire/ -- Silk Road Medical, Inc., a company dedicated to preventing the devastating
"TCAR is the next step," said Dr. Peter Schneider, Chief of Vascular Therapy at Hawaii Permanente Medical Group and Kaiser Foundation Hospital Honolulu, and National Co-Principal Investigator of the ROADSTER 2 post-market study. "Carotid endarterectomy has been perfected over 50 years, but no matter how good it gets, it has certain inherent challenges that aren't ever going to go away. My attitude now has really flip-flopped from that of tried and true surgery to what I think is the future of carotid artery repair."
TCAR is a clinically proven, minimally invasive and safe approach to treating carotid artery disease. The data from this year's VEITHsymposium add to the body of evidence supporting the use of Silk Road Medical's ENROUTE system. Presentations included:
"The clinical data presented at this year's VEITHsymposium add to the growing body of evidence supporting the use of TCAR as a new approach to treating carotid artery disease," said Erica Rogers, President and Chief Executive Officer of Silk Road Medical. "We are particularly excited by the interim analysis of our ROADSTER 2 post-market study. It is more than half way enrolled and showing comparable results to our ROADSTER 1 Pivotal Study, which reported the lowest stroke rate in any prospective study of carotid revascularization."
About Carotid Artery Disease and Stroke Every year, 15 million people worldwide suffer a stroke. Nearly 6 million die and another 5 million are left permanently disabled. Stroke is the second leading cause of disability globally. Ischemic strokes account for 80-90 percent of strokes, and an estimated 20-30 percent of these are caused by disease in the carotid arteries that carry blood to the brain. If left untreated, these blockages can fragment, flow to the brain and lead to a potentially disabling stroke, also known as a "brain attack."
About TCAR with the ENROUTE Transcarotid Neuroprotection and Stent SystemTCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The ENROUTE Transcarotid Stent is intended to be used in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) during the TCAR procedure. The ENROUTE Transcarotid NPS is a first in class device used to directly access the common carotid artery and initiate high rate temporary blood flow reversal to protect the brain from stroke while delivering and implanting the ENROUTE Transcarotid Stent.
About Silk Road MedicalSilk Road Medical, Inc. is a private company located in Sunnyvale, California, that develops and manufactures less-invasive medical devices intended to improve the treatment of vascular disease through proprietary transcarotid therapies. Detailed information can be found at www.silkroadmed.com.
ENROUTE is a registered trademark of Silk Road Medical, Inc.
View original content:http://www.prnewswire.com/news-releases/updated-tcar-data-from-silk-road-medicals-roadster-1-and-2-studies-presented-at-veithsymposium-300563812.html
SOURCE Silk Road Medical
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All